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4SUMMARY
Vaccination is different from most health interventions because it is preventative,
it protects against infectious disease (leading to knock-on effects), the diseases it
prevents are usually acute and self-limiting, and most vaccines are given to
children from whom it is very difficult to elicit preferences. Because of its unique
characteristics, vaccination may possess its own specific attributes. In this paper,
we estimate the average Willingness to Pay (WTP) for varicella vaccination and the
Quality-Adjusted Life-Years (QALY) lost due to chickenpox using Contingent
Valuation (CV), Standard Gamble and Health Utility Index Mark II (HUI2).
Furthermore, we identify what attributes of vaccination are important to vaccinees
and what elicitation technique can capture these components. To do this, we
administered computerised interviews to a sample of parents attending primary
Health Centres. Using CV we demonstrate that individuals are willing to pay more
for vaccination than treatment. Furthermore, we show that prevention of work loss
is an important intervention attribute for parents. On the other hand, consistent
with economic theory, the elicitation techniques used to estimate QALYs (Standard
Gamble and HUI2) did not capture non-health benefits. Finally, results elicited
using the CV were correlated with QALYs measured through the HUI2 questionnaire.
KEYWORDS: willingness to pay, standard gamble, quality-adjusted life-years,
vaccination, attributes.
5BACKGROUND
Most elicitation techniques have been developed for interventions that treat
chronic diseases in adults. Vaccination has different characteristics, which may
have an impact on which measures of benefit should be used when assessing the
impact of immunisation programmes: 
1) it is a preventative intervention, 
2) it protects against infectious disease resulting in externalities, 
3) the diseases it prevents can be short-lived and self-limiting,
4) most vaccines are given to young children from whom it is very difficult to elicit
health/program preferences. 
It has been argued that health is not the only source of well being derived from
public health interventions (1-3). For vaccinees, the overall benefit of vaccination
can be separated into 4 possible dimensions: 1) the direct effect on health, 2)
altruism, and 3) insurance type benefit, and 4) work loss.  To our knowledge no
study has attempted to quantify these different attributes.
Direct effect on health. The principal benefit that can be derived from
vaccination is that it prevents the vaccinee from acquiring disease and thus losing
health related quality of life. Other direct effects on health could be the side-
effects related to the vaccine itself.
Altruism. Preventing infection in a proportion of individuals in the population
offers a degree of protection to others in the population (4). Because of this, the
vaccinee (or vaccinee’s parent) may derive benefit from the knowledge that by
being vaccinated they will not infect other children (e.g. their siblings and friends).
Such a benefit can be called altruism (paternalistic or altruistic Altruism).
6Paternalistic or altruistic altruism occurs when individual A cares about individual
B’s consumption of health care and/or health status and this enters A’s utility
function (5,6).
Insurance type benefits. Immunisation offers protection against the uncertain
future event of catching disease and its consequences. In these terms, being
vaccinated can be viewed as taking insurance against disease. Because individuals
are generally risk averse in relation to health, they may find an added benefit in
the knowledge that they are protected against disease.  
Work loss. Individuals may also find benefit in that vaccination (of their children)
can also prevent them missing time off work or other inconveniences.
The feature that distinguishes between techniques of economic evaluation is the
way in which the benefits of health care programmes are valued. Surprisingly few
studies have directly compared WTP and QALY’s (7-9). The results raise questions
as to whether QALY’s and WTP would lead to similar decisions concerning the
allocation of health resources. Furthermore, no study has compared QALY’s and
WTP for immunisation, small changes in well-being or have examined if QALY’s are
truly incapable of measuring individuals non-health benefits. 
The objectives of this paper are threefold: 1) to estimate Willingness to Pay for
varicella vaccination using Contingent Valuation (CV) and the Quality Adjusted Life
Years (QALY) lost due to chickenpox from Standard Gamble (SG) and the Health
Utilities Index mark 2 (HUI2), 2) to compare results from the various elicitations
techniques, and 3) identify what attributes of vaccination these elicitation
techniques can capture. 
7METHODS
Ethical approval, Sampling and Survey design
Ethical approval was granted by the Public Health Laboratory Service (PHLS) ethics
committee and the Barnet, Enfield and Haringey Local Research Ethic Committee. 
The study population consists of parents. Parents were used as proxies for their
children since at the time of chickenpox vaccination (or disease) the child is too
young to reveal his/her preferences (10-12). Furthermore, it is the parent who
decides whether or not their child is vaccinated. We recruited all parents
regardless of whether or not their children had prior history of varicella. For
ethical reasons, the only exclusion criterion was age greater than 18 years.
Parents and caregivers were recruited from primary Health Centres in Enfield,
London at the time of routine infant and child check-ups. Parents were approached
in the waiting room where they were given an information leaflet and asked to
participate in the study. Those consenting to participate were given a computer
active interview. 
Questionnaires 
The computerised questionnaire was programmed in Visual Basic within Microsoft
Access. Before the start of the main study, a pilot study was conducted to finalize
the questionnaire. The computer active pilot questionnaire was administered to 89
parents. From the pilot we concluded that respondents had little difficulty
answering the questionnaires and that the bidding scales used produced adequate
distributions. The final computer active questionnaire is structured into 3 parts and
is available from the authors on request. 
8Part 1: Socio-demographic questionnaire. In part 1, respondents were asked
standard socio-demographic questions including age, sex, level of education and
annual income. Respondents were asked whether their children are fully
vaccinated for their age in order to have an idea of the parent’s general attitude
towards vaccination; if they need to take time off work when their child is sick;
and whether any of their children have had chickenpox.   
Part 2: Contingent Valuation or Standard Gamble questionnaire. In part 2,
respondents were given one of two different types of questionnaire: 1) CV and 2)
SG. Each parent or caregiver responded to only one type of question. 
Contingent Valuation: The respondents were given a description of the health
profile of a child with chickenpox (Box 1). Initially respondents were asked to
assume that their child has chickenpox and that a drug exists which can cure their
child immediately. We then elicited the maximum the respondent is willing to pay
for the drug using a bidding algorithm (Table 1). In the second section of the CV
questionnaire, respondents were asked the maximum they were willing to pay to
vaccinate their child against chickenpox (i.e. to prevent their child having
chickenpox sometime in the future). We used the ex-post user-based perspective
(respondents were asked to assume they are at the point of intervention) for
comparability with the SG, which has a similar perspective. However, as
immunisation offers protection against the uncertain future event of catching
disease the second section (vaccination question) has characteristics of insurance-
based questions (i.e. respondents are at the point of intervention but not in the
disease state). 
9Respondents were given randomly one of 4 different contingent valuation
questionnaires. The questionnaires differed in their description of the effectiveness
and consequences of the intervention. Table 2 describes the different components
included in the 4 questionnaires. By comparing the willingness to pay between and
within the different questionnaires it was possible to estimate the value parents
place on vaccination and its different attributes.
Overall benefit of chickenpox vaccination in vaccinees: This is estimated by
assessing the average willingness to pay for chickenpox vaccination when
effectiveness is 85% (as estimated from clinical studies (13)). 
Attributes of vaccine programmes: The direct health effect of preventing a case of
chickenpox was measured by estimating the average willingness to pay for
chickenpox treatment when efficacy is 100%. It should be pointed out that,
following the request from the ethics committees, parents were asked to assume
that vaccination and treatment had no side effects. The value parents’ put on
preventing their child infecting others (altruism) was measured by comparing the
WTP from questionnaires stressing this effect to those in which the effect was not
mentioned. The benefit of security (insurance type benefit) was measured by
comparing the difference in parent’s willingness to pay for treatment and
vaccination. Finally, the value of parental work loss was measured by estimating
whether parents who must take time off work when their child is ill are willing to
pay more to prevent chickenpox than those who do not, controlling for factors such
as household income. 
Standard Gamble: A separate group of respondents were asked to imagine that
their child is in an imaginary health state for 15 years (see Box 2 for description).
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The duration of disease was chosen so that parents would trade risks of death for
intervention and it is the time-span of childhood. Apart from the duration of
disease, the health profile is identical to the description of chickenpox. Interviews
using the CV and SG questionnaires were given on different days. 
Respondents were given randomly one of 2 different SG questionnaires. The only
attribute varied in the SG questionnaire was altruism. In half of the questionnaires
altruism was included by stressing that treatment will prevent the child from giving
the disease to other children. In the remainder there were no mention of knock-on
effects. Probabilities were presented numerically and visually to make clear the
risks that were being traded-off. Visual aids were similar to those presented by
Appel et al. (14), and are available on request.  
Experimental design 
The experimental design used was a combination of conjoint analysis and CV or SG.
That is, we present individuals with various scenarios that include different
attributes (conjoint analysis) and from which we obtain preferences using CV or SG.
Respondent’s maximum WTP or maximum acceptable risk to return to perfect
health (SG) was assessed using bidding algorithms (see Table 1). Starting point bias
has been identified in such algorithms (8,15,16).  To test and control for starting
point bias, we used three randomised starting bids for the CV and SG questions
(Table 1). 
Part 3: Health Utilities Index mark 2 (HUI2) questionnaire. In part 3 we ask the
respondents to rate the health state that has been described to them (chickenpox
(CV) or the imaginary disease (SG)) using an existing generic health status index
(Health Utilities Index mark 2 (HUI2)). This enables us to estimate the QALY loss
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due to chickenpox as well as validate the WTP and SG responses. Because it was
developed for childhood diseases using parents as proxies and utilities were derived
using SG (17), HUI2 is an ideal tool to validate responses from Part 2 (CV and SG
questionnaires). 
Data Analysis
CV and SG model. The respondents’ answers to the questions did not directly
reveal their maximum WTP (CV) or their maximum acceptable risk to return to
perfect health (SG). The responses only provided bounds. For example, a
respondent who replied yes to £100 but no to £150 is assumed to have a WTP value
between £100 and £150. Furthermore, the data are both right and left censured.
That is, the lowest bid for WTP was £0 (0.1% for SG) and highest £200 (20% for SG).
Interval regression was used because it can estimate models for point, interval and
censured data. Using this method we estimated the average WTP for chickenpox
treatment and vaccination (CV) and average acceptable risk (SG). Furthermore, we
tested which intervention and respondent attributes affected the results as well as
whether there was starting point bias. The variables and attributes included in the
regression are listed and described in Table 3.
Analyses were carried out in Stata v.7.0. (StataCorp, 2002). The data generated
from the study sample were re-weighted to be representative of the population of
parents with children of vaccination age in England. Weights for the CV and SG
analyses are presented in Table 4. The final multivariable models used to estimate
the average WTP and SG and to identify significant variables were selected using
the following method. Firstly, univariable analyses identified variables that were
significant (p<0.2 level) for inclusion in the multivariable models.  Secondly, the
identified variables were added to the model and retained if they remained
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significant (p<0.1 level). Finally, the variables that were excluded at the
univariable stage were included one by one to assess whether they became
significant. 
Analysis of refusals. In the CV questionnaire respondents have the option to not
accept the intervention even at zero cost (equivalent to refusing chickenpox
treatment and vaccination for their children). We used logistic regression to
examine determinants of the decision to refuse chickenpox intervention. In the
analysis, the dependant variable was 0 if the respondent refused intervention and 1
otherwise with independent variables presented in Table 3.
QALY-weight estimation. As described above, the average maximum risk of
instant painless death parents were willing to accept for their children was
estimated using interval regression. From this a QALY-weight can be estimated
using the standard technique and compared to those estimated from the HUI2
system using the scoring formula published by Torrance et al. (17). The overall
average QALY-weight and determinants was assessed using linear regression.  The
variables included in the regression are listed in Table 3. Both responders to the CV
and the SG filled in the HUI2. The description of disease was identical in the two
questionnaires apart from duration. That is, in the CV questionnaire the disease is
assumed to be for a week and in the SG it is assumed to last for 15 years. We term
HUI2-CV and HUI2-SG the Health State described to CV and SG respondents
respectively. By comparing HUI2-CV and HUI2-SG we test whether duration of
disease has an impact on QALY weight as measured by HUI2.
RESULTS
CHARACTERISTICS OF RESPONDENTS 
13
Table 4 presents the characteristics of the 202 and 63 parents who answered the
CV and SG questionnaire respectively, and how they compare to women with
children under 5 years in the general population of England. Because, there were
fewer attributes tested in the SG questionnaire, the sample size was lower than
the CV questionnaire. The characteristics of parents who responded to the
questionnaires were similar (Table 4). Because the setting was in baby clinics, the
parents interviewed had very young children. This was intended, as we sought to
recruit parents of children that were close to the age of vaccination and who were
susceptible to chickenpox. Compared to national statistics (www.statistics.gov.uk),
the parents of the sample were older, more educated and had a higher household
income (see Table 4 for details). 
WILLINGNESS TO PAY – CV QUESTIONNAIRE
Distribution of WTP responses
All respondents to the CV questionnaire (202 parents) were asked their WTP for
both chickenpox vaccination and treatment. Twenty-nine and 31 parents said they
would not have their child treated and vaccinated, respectively, even if it was
free. Of the parents who were willing to have their children both treated and
vaccinated, 49 were WTP more for vaccination, 5 were WTP more for treatment
and 111 provided identical WTP. Using McNemar’s test for paired data, the WTP for
vaccination was found to be significantly higher than for treatment (χ2=34, p-
value<0.0001). This suggests that parents find an added benefit in prevention – i.e.
that insurance type benefits exit.
WTP analysis 
The WTP analysis is divided into 3 sections. First, we analyse the complete dataset
assessing the average overall preference of parents taking into account those who
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would refuse the intervention even if it were free. In the second section, we
examine the variables, which determine whether or not parents refuse chickenpox
treatment or vaccination. Thirdly, we analyse the WTP of parents who desire
chickenpox treatment and vaccination for their children.
WTP analysis with refusals. Results from the interval regression model are
presented in Table 5. Significant variables (p < 0.05) for both the WTP for
treatment and vaccination were Vaccinated, Work Loss, Income, HUI2 and Start
Bid. Parents of children who are fully vaccinated for their age (Vaccinated=0) are
willing to pay £107 and £134 more for chickenpox treatment and vaccination,
respectively than those who are not. Furthermore, controlling for other variables,
parents who must take time of work when their children are sick (Work loss=0) are
WTP £32 (£38) more for treatment (vaccination). Results also suggest there is
starting point bias. WTP for treatment and vaccination is significantly higher for
respondents who were given the £75 starting bid (start bid: p<0.05 Table 5).
Finally, as expected by theory, WTP increases with the household income (income:
p<0.05) and with perceived severity of chickenpox (HUI2: p<0.05). It should be
noted that altruism and efficacy were not found to be significant factors in parents
WTP for chickenpox treatment and vaccination. 
Analysis of refusals. Table 6 reports the results from the logistic regression of
acceptance/rejection of chickenpox treatment and vaccination. Significant
variables are Vaccinated, Work and HUI2. Parents of children who are fully
vaccinated for their age (Vaccinated=0) are estimated to be 6 (1/0.16) times more
likely to accept treatment or vaccination. Furthermore, parents who work
(Work=1) were 3 times more likely to accept intervention against chickenpox.
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Finally, those who accepted treatment or vaccination thought chickenpox to be
more severe then those who did not. 
WTP analysis without refusals. Table 7 reports the results from the interval
regression model of WTP of parents who desired chickenpox treatment or
vaccination for their children. Significant variables for both the WTP for treatment
and vaccination were Work Loss and Income. Controlling for other variables,
parents who must take time off from work when their children are sick (Work
loss=0) were willing to pay £26 (£24) more for treatment (vaccination).
Interestingly, the perceived severity of chickenpox was not significant in the
amount parents were WTP. Thus, perceived severity seems to be a significant
factor in whether or not parents would want their child to be treated (or
vaccinated – Table 6) against chickenpox but not the amount they are WTP (Table
7). Once parents have decided they were willing to treat (or vaccinate) their
children, the most important factor in their maximum WTP for intervention was
their income (i.e. their capacity to pay). Altruism and efficacy were not found to
be significant factors in parents WTP. 
Mean Willingness to pay. Table 8 presents the estimated average WTP for
chickenpox treatment and vaccination for the study sample and the population of
England. The average WTP for the sample is higher than for England because it has
a higher income, higher level of education and older population. From Tables 5-7 it
is possible to estimate the monetary value of the various attributes of varicella
vaccination. Altruism was not significant in the WTP models. In our sample, the
insurance type benefit is estimated to be £18.84 (£140.45 – £121.61, Table 8).
Furthermore, the average value of parental work loss in the sample was £10.72 per
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individual (£26.41*Proportion of parents who do not take time of work (41%), Table
4 and 5).
QUALITY-ADJUSTED LIFE-YEARS – SG QUESTIONNAIRE
Table 9 reports results from the interval regression model of parents’ maximum
acceptable risk. Fathers were willing to take, on average, a 7% greater risk of
death for their child to return to normal health than mothers. Furthermore,
respondents without a degree were, on average, willing to take a 6% higher risk
than those with a degree. Parents who were told their child could transmit the
imaginary disease to other children were willing to accept a 5% greater risk of
death than those who did not. 
The average risk of death accepted by respondents was 9% (95%CI 7%-11% - Table
8). This corresponds to a QALY-weight of 56% (95% CI: 45%-66%). The average risk of
death that would be acceptable to parents is predicted to be higher for the
population of England (14%; resulting QALY-weight 31%) than for the study sample,
because the study sample has a high proportion of parents with a degree. 
QUALITY-ADJUSTED LIFE-YEARS - HUI2 QUESTIONNAIRE
Table 10 reports results from the regression model of QALY-weights elicited from
respondents of the CV and SG questionnaires, respectively, using the HUI2 system.
For respondents of the CV questionnaire, the single significant variable was
Chickenpox. Respondents whose children had not had chickenpox (Chickenpox=1)
believed chickenpox to be more severe (lower QALY-weights). For respondents of
the SG questionnaire, Altruism was the lone significant variable. Parents who were
given the altruistic questionnaire had a significantly lower QALY-weight. The
standard gamble and HUI2-SG produced identical QALY-weights (56%). However,
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this was significantly different from the 76% (95% CI: 74%-78%) calculated from
HUI2-CV.
DISCUSSION
In this paper we used various elicitation techniques (CV, SG and HUI2) to estimate
parent’s WTP for varicella vaccination and the QALY lost due to chickenpox and to
identify the different attributes of vaccination.
Conjoint valuation. The average WTP for parents who desired varicella
vaccination, corrected to represent the population of England, was £120.21. Three
attributes of vaccination were measured: 1) direct health benefit, 2) insurance
type benefit, and 3) parental work loss (Table 8). The direct health benefit,
insurance type benefit and work loss represented 79%, 13% and 8% of the average
WTP for vaccination respectively. To our knowledge, this is the first study to show,
empirically, that individuals prefer vaccination (prevention) to treatment and that
quantifies parent’s WTP to prevent work loss.
WTP for vaccination was significantly greater than for treatment indicating that
individuals find an added benefit in the security that their child will not develop
chickenpox (insurance type benefit). In theory, this is expected since individuals
are risk averse and therefore there exists a potential for improving welfare by
reducing or eliminating uncertainty. Previous studies have shown that the expected
WTP assuming risk neutrality (WTP to treat, ex post, multiplied by the risk of the
event) is lower than the elicited WTP using the ex ante insurance-based question
(18,19). Here, there is a difference in that both the treatment and vaccination
questions are ex post user-based. Furthermore, the risk of acquiring chickenpox is
close to 100%. Hence, contrary to previous studies (18,19), the insurance type
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benefit that is quantified cannot be biased because of differences in the valuation
perspective (ex ante vs. ex post) or individuals misunderstanding the risks of
disease. It should be pointed out that, in our calculation of the insurance type
benefit, we do not take into account discounting, which would render the added
benefit of vaccination greater. Since chickenpox occurs on average at 6 years of
age in the UK, the present value of treatment (assuming discounting) will be lower
than the elicited WTP, which supposes the child is currently unwell.
Work loss was a significant factor in parents WTP for vaccination after controlling
for other factors such as income. This raises questions of whether prevention of
work loss should be included in the denominator of the cost-benefit ratio (is a
benefit), the numerator (is a societal productivity gain) or both. Care must be
taken when conducting Cost-benefit analysis not to double count these
cost/benefits.  
Although other studies have found evidence of altruism (20-22), it was not
identified as a significant variable in this study. Previous studies measured altruism
by comparing private versus public WTP for an intervention (7). That is, they
measured respondent’s preference for subsidising fellow citizens’ health care
(caring externality (23)). Here, we attempted to measure a different type of
altruism, which is specific to prevention of infectious diseases. We estimated
whether individuals derive benefit from not infecting others (i.e. family and
friends) because they are immunised. This benefit may not have been detected in
our analysis because of the lack of power of the study to measure very small
differences in WTP, because chickenpox is too mild to produce such altruistic
benefits, or because this particular type of altruism does not exist. Further
research is needed on this issue.   As expected by economic theory, WTP increased
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with perceived severity of disease (HUI2) and income. However, contrary to other
studies, effectiveness of the vaccine was not found to be a significant factor in
parent’s decision to vaccinate (24,25). This is most likely because, parents were
told that although the vaccine had 85% effectiveness; cases among vaccinated
children were very mild. 
Validations of CV studies are very difficult due to the hypothetical nature of the
questions (8,26). In this study, responses to the CV questionnaire were consistent
with expected theory. WTP for vaccination (and treatment) increases with income
until a point at which it starts to decline (construct validity - Tables 5 and 7).
Secondly, the perceived severity of disease as measured by the HUI2 system
significantly affected parents overall WTP for chickenpox vaccination and
treatment, which demonstrates convergent validity and that WTP increases with
perceived benefits (Table 5). 
Standard Gamble. The average QALY-weight estimated from the SG analysis was
56% for the study sample and 31% when adjusted for the overall population of
England. Work loss was not found to be a significant factor of the SG. This result is
consistent with the general belief that QALYs cannot capture non-health benefits
(3,27). 
The effect of Altruism, Gender and Degree were significant (Table 9). The QALY-
weight elicited from parents who were told that intervention would prevent their
child giving the disease to other children was 0.25 lower than those who did not
have this attribute. This may be an altruistic or a paternalistic externality or a
direct health valuation. We show that parents who were given the altruistic
scenario believe that the disease was more severe (the QALY-weight derived from
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the HUI2-SG questionnaire was significantly higher (Table 10)). Hence, it is more
likely that the SG did not capture externalities but actual valuations of health. 
Fathers were willing to take greater risks to return their children to normal health
(QALY-weights were 0.35 lower than for mothers). This is consistent with other
studies, which show that for an identical health state QALY-weights elicited from
women are higher (28,29). Finally, having a degree was found to be significant,
which suggests that understanding of risk may be an important factor in standard
gamble elicitation despite the fact that visual aids were used. This corroborates a
previous study (18). That gender and level of education influence SG responses may
raise equity concerns. 
Health Utility Index mark 2. The QALY-weight distributions estimated from the
HUI2 system were much lower in those given the HUI2-CV compared with HUI2-SG
questionnaires (0.76 vs. 0.56 – Table 8). The only differences between the CV and
SG disease descriptions were that duration of disease was extended to 15 years in
the SG questionnaire (in order for parents to trade-off probabilities that they could
understand), and parents who were given the CV questionnaire were told they
were valuing chickenpox. Difference between the QALY-weight elicited from HUI2-
CV, HUI2-SG and the SG questionnaires illustrate the measurement problems of
estimating QALY-weights for acute diseases using SG and similar elicitation
methods. The main problem is that, for acute and mild diseases, such as
chickenpox, the rational risk that individuals should be willing to trade-off is too
small for most to comprehend. To get around this we can increase the duration of
the disease state, assuming constant proportional trade-off, while keeping the
same health state description. Here, this technique does not seem to work. This
can be due to two reasons. Firstly, the proportional trade-off assumption may not
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hold. Many studies in the literature show that the QALY-weight is dependent on the
time individuals are in the disease state (30-35). The second problem is that by
increasing duration of disease and refraining from mentioning chickenpox,
individuals are actually rating an imaginary disease that they have difficulty
understanding. That is, parents are rating a different disease. This seems to be the
case as HUI2-CV and HUI2-SG give different QALY-weights. 
As mentioned earlier, the HUI2 system and other multi-attribute health status
classification systems have two major advantages over SG when estimating the
morbidity of infectious diseases: 1) they are simple to understand and answer and,
2) they can capture small changes in heath status (36,37). In this study individuals
who responded to the HUI2-CV had little difficulty responding to the questionnaire.
This was aided by the fact that chickenpox was known to most parents. Despite
this, QALY-weights were significantly higher for parents of children with positive
history of the disease (Table 10), which raises the question about who should be
answering elicitation questionnaires. Should it be those who are at risk or affected
by the disease or the general public? De Wit et al. (36) consider this question in
detail.
Limitations of the analysis. The analysis presented here has four main
limitations: 1) it uses parents as proxies, 2) a bidding algorithm was used, 3) the
impact of vaccine side effects and risk of disease on WTP and SG were not directly
elicited, 4) a vaccination scenario was not included in the SG questionnaire. 
Parents are used as proxies. Varicella vaccination is mainly carried out on very
young children, from whom it is impossible to elicit preferences. We used parents
as proxies as they are the ones who are responsible for the health of their children
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and decide whether they receive vaccination. A number of problems have been
observed when using parents as proxies (38). Firstly, for multi-attribute health
systems, although results are correlated between parents and children, parents
report a greater effect of illness on the quality of life of their child (39-42). This
has also been observed to be true when comparing elicitation techniques between
patients and other proxies (36). On the other hand, parents may be more risk
averse for their children than for themselves. Hence, SG using parents as proxies is
likely to underestimate the QALYs lost. Secondly, if parents are used as proxies,
QALY and WTP measures may integrate to some degree the indirect effects on the
parents (e.g. psychological, monetary). A good example of this is that parents who
must take time off work are willing to pay more for vaccination. 
Impact of vaccine side effects and risk of disease on coverage and WTP. Decision to
immunise or not is influenced by individuals’ fear of side effects and the severity of
disease (43). However, as mentioned above, we could not measure the extent to
which these factors have an effect on vaccine coverage and WTP for vaccination
because of ethical considerations. Although varicella vaccine side-effects are
typically mild (44-46), results from the CV may overestimate parents WTP for
vaccination. 
Bidding game. To increase precision and the power of our study to detect
attributes, we used a bidding game (iterative-close ended questioning approach) to
elicit maximum WTP, which may induce starting-point bias (16,47-51). Starting
point-bias was identified here (Table 5), though it was controlled for when
estimating the values of the different attributes of vaccination. Furthermore,
starting-point bias was not a significant factor when assessing the maximum WTP
for vaccination or treatment when excluding responses of those who refused
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intervention. 
A vaccination scenario was not included in the SG questionnaire. We did not
include a vaccination scenario in the SG questionnaire because of ethical reasons.
When ethical approval was originally sought (in 2001), vaccine coverage had
dropped in the UK due to the alleged concern of the safety of the MMR vaccine.
Including a scenario in which vaccination could cause death in a proportion of
children could have provoked more worry in parents and have had deleterious
consequences on vaccine coverage.
Strengths of the analysis. For the CV questionnaire we follow Carson et al.’s (52)
conditions for a valid CV scenario and National Oceanic and Atmospheric
Administration (NOAA) recommendations (53). As recommended by the NOAA panel
we used face-to-face interviews, reminded respondents that the money is from
their own disposable income (out-of-pocket), used a binary CV format and
demonstrated sensitivity of scope.
The analysis presented here expands the health economic literature in two major
areas. We present for the first time empirical evidence that individuals prefer
prevention to treatment (insurance type benefit exist) and that in their decision to
accept an intervention for their children, parents value the benefit of preventing
time off work (work loss benefit). This study is also the first to assess, using
empirical results, the advantages/disadvantages of different elicitation techniques
in the context of valuing the benefit of vaccination. 
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Table 1. Bidding Scales and Bidding algorithms for WTP and SG questions 
WTP 
Bid Scale 
SG 
Bid Scale 
 
 
Bid 
Algorithm 1 
 
     
  
 
Bid 
Algorithm 2 
 
 
 
 
Bid 
Algorithm 3 
 
 
£0 0.1%   •   •   •  
£10 0.5% N  •  N • Y N  •  
£25 1% N Start Y  •  N  • Y 
£50 2%   •  N Start Y  •  
£75 5% N • Y  •   Start Y 
£100 10%   •  N • Y  • Y 
£150 15% N • Y  • Y  •  
£200 20%  •   •   • Y 
Y, willing to accept the bid, N not willing to accept the bid. 
For SG, if a person is indifferent we stop the bidding. 
N 
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Table 2. Attributes varied in the CV questionnaires
Efficacy AltruismC
100%A 85%B
WTP Questionnaire 1 U U
WTP Questionnaire 2 U
WTP Questionnaire 3 U U
WTP Questionnaire 4 U
A. 100% efficacy for Treatment was described as follows: With the drug your child will return immediately to
normal health. 100% efficacy for Vaccination was described as follows: With the vaccine your child will never get
chickenpox.
B. 85% efficacy for Treatment was described as follows: With the drug your child has an 85% chance of being
immediately cured, and a 15% chance of getting mild chickenpox. 85% efficacy for Vaccination was described as
follows: With the vaccine your child has an 85% chance of never getting chickenpox, and a 15% chance of getting
mild chickenpox.
C. Altruism was described as follows:  With the drug (or vaccine) you prevent your child from giving chickenpox to
other children.
U indicates that the attribute is included in the description of the intervention.
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Table 3. Independent variable specification 
Variable Description
Gender 0=female, 1=male
Age age in years
Degree 0=degree, 1=no degree
Work 0=does not work, 1=works 
Vaccinated 0=children are fully vaccinated for their age, 1=children are not fully
vaccinated, 9=don’t know or did not answer
Work loss 0=Need to take time off work when child is sick, 1=Does not need to take
time off work
Children 1=1 child, 2=2 children, 3=3 children, 4=4 or more children, 9=did not
answer
ChickenpoxA 0=at least one child has had chickenpox, 1=no child has had chickenpox,
9=don’t know or did not answer
People 1=1 person in the household, 2=2 people in the household, 3=3people in
the household, 4=4 people in the household, 5=5 people in the
household, 9=did not answer
Income 0=annual household income before tax is less than £15,000, 1=£15,000-
24,999, 2=£25,000-39,999, 3=£40,000-59,999, 4=more than £60,000, 9=
did not answer
AltruismB 0=altruism, 1=no altruism
EfficacyA,B 0=100% efficacy, 1=85% efficacy
HUI2B QALY weight of chickenpox as measured by the HUI2 system
Start Bid 0= start bid is £25 (CV) or 1% (SG), 1= start bid is £50 (CV) or 2% (SG), 2=
start bid is £75 (CV) or 5% (SG)
A. Not included in the SG analysis. 
B. Not included in the HUI2 analysis.
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Table 4. Characteristics of respondents 
CV SG Population CV SG
N (%) N (%) %
Under-
representation
Under-
representation
Gender
  Male 18 (9%) 7 (11%)
  Female 183 (91%) 56 (89%)
Age (years)
  <  20 5 (2%) 2 (3%) (8%)A 0.31 0.40
  20-29 65 (32%) 25 (40%) (47%) 0.68 0.84
  30-39 124 (61%) 31 (49%) (43%) 1.43 1.14
  40+ 8 (4%) 5 (8%) (2%) 1.98 3.97
Degree
  Yes 96 (48%) 31 (49%) (28%)B 1.70 1.76
  No 106 (52%) 32 (51%) (72%) 0.73 0.71
Work
  No 84 (42%) 22 (35%) (46%) C 0.90 0.76
  Yes 118 (58%) 41 (65%) (54%) 1.07 1.21
Number of children
  1 123 (61%) 43 (68%)
  2 63 (31%) 15 (24%)
  3 14 (7%) 4 (6%)
  4+ 2 (1%) 1 (2%)
Age of children (years)
  0 149 (53%) 43 (48%)
  1-4 100 (36%) 33 (37%)
  5+ 32 (11%) 13 (15%)
Children fully vaccinated
  yes 186 (92%) 56 (89%) (86-94%) D
  no 9 (4%) 5 (8%)
  don't know or n.a. 7 (3%) 2 (3%)
Work loss when child is
sick
  yes 83 (41%) 30 (48%)
  no 119 (59%) 33 (52%)
Child with chickenpox
  yes 42 (21%) (23%)E 0.90
  no 157 (78%)
  don't know or n.a. 3 (1%)
Number of people in
household
  1 1 (0%) 1 (2%)
  2 14 (7%) 3 (5%)
  3 102 (50%) 35 (56%)
  4 65 (32%) 17 (27%)
  5+ 19 (9%) 6 (10%)
Household income before
tax
 <£15,000
 £15,000-24,999
 £25,000-39,999
 £40,000-59,999
 £60,000+
 na
19
27
51
47
36
22
(9%)
(13%)
(25%)
(23%)
(18%)
(11%)
2
10
22
12
8
9
(3%)
(16%)
(35%)
(19%)
(13%)
(14%)
(12%)F
(16%)
(30%)
(16%)
(12%)
(14%)
0.78
0.79
0.81
1.37
1.49
0.27
0.97
1.17
1.16
1.10
A. Birth Statistics, 1999: age of mother: Live births (Office of National Statistics); B. Labour Force Survey, 2000 -
women aged 25-44 (Office of National Statistics); C. Labour Force Survey, 2000 - Economic activity status of
women: by marital status and children aged less than 5 years (Office of National Statistics); D.
http://www.hpa.org.uk/cdr/PDFfiles/2001/cdr2501.pdf - Proportion of fully vaccinated children by 24 months in
UK; E. Predicted % of seropositive children using the sero-profile estimated in Brisson et al. (54); F. Family
Expenditure Survey 1999-2000 - Characteristics of households: by children aged less than 5 years.
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Table 5. WTP - Interval regression model with refusals
WTP for Treatment WTP for Vaccination
Coef [95% CI] P>|z| Coef [95% CI] P>|z|
Constant 169.44 (89.48 to 249.39) 0.000** 187.39 (87.02 to 287.77) 0.000**
Vaccinated
   0
   1
   9
0
-107.36
-53.61
Baseline
(-173.68 to -41.04)
(-139.89 to 32.66)
0.009**
0
-134.24
-55.45
Baseline
(-220.12 to –48.36)
 (-161.18 to 50.28)
0.012**
Work loss
   0
   1
0
-31.55
Baseline
(-58.78 to -4.32)
0.023**
0
-38.12
Baseline
(-72.11 to  -4.12)
0.028**
Income
   0
   1
   2
   3
   4 
   9
0
13.44
35.29
66.81
58.51
44.38
Baseline
(-41.48 to 68.36)
(-14.02 to 84.60)
(16.95 to 116.67)
(5.23 to 111.79)
(-14.14 to 102.91)
0.062*
0
18.15
41.50
74.16
64.64
34.04
Baseline
(-50.13 to 86.43)
(-19.64 to 102.63)
(11.92 to 136.40)
(-2.01 to 131.30)
(-39.11 to 107.18)
0.098*
Start Bid
   0
   1
   2
0
-2.55
35.10
Baseline
(-34.69  to –29.58)
(2.64 to 67.56)
0.037**
0
-28.50
30.87
Baseline
(-68.81 to 11.83)
(-9.55 to 71.28)
0.014**
HUI2 -131.11 (-213.35 to -48.86) 0.002** -130.44 (-233.61 to –27.27) 0.013**
σ 89.18 (77.52 to 100.83) 109.75 (94.00 to 125.50)
Log
likelihood
-408.63 -395.26
Null Log-
likelihood
-430.06 -414.02
LRχ2(12) 42.83 0.000** 37.52 0.000**
Sample size 202 202
* Significant at p<0.1; ** Significant at p<0.05
Table 6. Analysis of Refusals - Logistic regression model
WTP for Treatment WTP for Vaccination
Odds
Ratio
[95% CI] P>|z| Odds
Ratio
[95% CI] P>|z|
Vaccinated
   0
   1
   9
1
0.16
0.25
Baseline
(0.03 to 0.83)
(0.03 to 1.99)
0.034**
1
0.16
0.11
Baseline
(0.04 to 0.72)
(0.01 to 0.79) 
0.003**
Work
   0
   1
1
3.29
Baseline
(1.41 to 7.68)
0.010**
1
2.93
Baseline
(1.39 to 6.20)
0.004**
HUI2 0.001 (0.00 to 0.08) 0.002** 0.07 (0.00 to 1.04) 0.041**
Log
likelihood
-74.08 -90.86
Null  Log
likelihood
-89.93 -103.26
Model χ2(4) 30.99 0.000** 23.87 0.000**
Sample size 200 200
* Significant at p<0.1; ** Significant at p<0.05
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Table 7. WTP - Interval regression model without refusals
WTP for Treatment WTP for Vaccination
Coef [95% CI] P>|z| Coef [95% CI] P>|z|
Constant 88.28 (48.05 to 128.512) 0.000** 97.24 (52.28 to 142.21) 0.000**
Work loss
   0
   1
0
-26.15
Baseline
(-49.95 to –2.36)
0.050**
0
-24.41
Baseline
(-51.17 to 2.34)
0.074*
Income
   0
   1
   2
   3
   4 
   9
0
22.89
44.07
61.49
60.09
84.90
Baseline
(-24.51 to 70.29)
(2.36 to 85.77)
(19.77 to 103.21)
(14.94 to 105.24)
(34.02 to 135.79)
0.010**
0
34.16
42.20
79.58
82.13
84.19
Baseline
(-18.8 to 87.15)
(-3.81 to 88.21)
(32.38 to 126.77)
(30.40 to 133.86)
(27.06 to 141.33)
0.005**
σ 73.73 (64.06 to 82.68) 79.43 (68.50 to 90.37)
Log
likelihood
-354.54
-320.63
Null Log-
likelihood
-365.71 -332.27
LRχ2(12) 22.34 0.001** 23.28 0.001**
Sample size 173 171
* Significant at p<0.1; ** Significant at p<0.05
Table 8. Mean WTP and QALY 
EnglandA Sample
Mean [95% CI] Mean [95% CI]
WTP analysis
  WTP for Treatment
   With Refusals 90.08 (75.21; 104.95) 98.38 (83.95; 112.81)
   Without Refusals 104.63 (89.25; 120.01) 121.61 (109.39; 133.81)
  WTP for Vaccination
   With Refusals 96.16 (78.92; 113.41) 105.42 (87.58; 123.26)
   Without Refusals 120.21 (103.18; 137.24) 140.45 (126.42; 154.50)
  WTP For Vaccine Attributes
   Direct Health Benefit 93.81 110.89
   Altruism 0.00 0.00
   Insurance Type Benefit 15.68 18.84
   Parental Work loss 10.72 10.72
SG Analysis
   Risk of death 13.74 (8.43 to 19.05) 8.88 (6.80 to 10.95)
QALY analysis
  HUI2-CVB  all children 0.75 (0.72 to 0.78) 0.76 (0.74 to 0.78)
  HUI2-CVB  history of chickenpox 0.81 (0.75 to 0.87) 0.82 (0.77 to 0.87)
  HUI2-SGC 0.57 (0.48 to 0.66) 0.56 (0.52 to 0.61)
  SG 0.31 (0.05 to 0.58) 0.56 (0.45 to 0.66)
A. Data generated from the study sample re-weighted to represent the population of parents with
children of vaccine age in England. Weights used are presented in Table 4. 
B. See Appendix for description of chickenpox. 
C. See Appendix for descrition of imaginary disease.
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Table 9. SG - Interval regression model
Coef [95% CI] P>|z|
Constant 10.05 (4.34 to 15.77) 0.000**
Altruism
   0
   1
0
4.96
Baseline
(1.23 to 8.70)
0.009**
Gender
   0
   1
0
-7.27
Baseline
(-13.20 to –1.35)
0.016**
Degree
   0
   1
0
6.12
Baseline
(2.49 to 9.75)
0.001**
σ 7.10 (5.64 to 8.55)
Log likelihood -158.17
Null Log-likelihood -166.72
LR χ2(3) 17.08 0.001**
Sample size 63
**Significant at p<0.05
Table 10. HUI2 - Regression model
Coef [95% CI] P>|z|
HUI2 – CV questionnaire
  Constant 0.824 (0.777 to 0.872) 0.000**
  Chickenpox
    0
    1
    9
0
-0.077
-0.188
Baseline
(-0.130 to –0.023)
(-0.371 to –0.004)
0.008**
  Sample size 202
HUI2 – SG questionnaire
  Constant 0.608 (0.546 to 0.670) 0.000**
  Altruism
    0
    1
0
-0.101
Baseline
(-0.194 to –0.008)
0.034*
  Sample size 63
** Significant at p<0.05
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APPENDIX
Box 1.
Description of Chickenpox 
• Typically, chickenpox lasts for 7 days 
• During this time, your child: 
1. Is covered (face, body and arms) with up to 500 red spots that 
itch intensely, which is highly frustrating 
2. Has mild fever with cold-like symptoms  
3. Has problems sleeping 
4. Has no problems walking about 
5. Cannot go to school or day care until all the spots have dried or 
crusted.  
6. Has problems with performing his/her usual activities (e.g. 
hobbies, sport, playing) 
 
• Working parents take an average 2 days off work per case of 
chickenpox 
 
 
 
Description of Mild Chickenpox 
• Typically, mild chickenpox lasts for 5 days 
• During this time, your child: 
1. Has only a few red spots  
2. Has no fever or problems walking about 
3. Has some problems with performing his/her usual activities 
(e.g. hobbies, sport, playing) 
4. Misses 1 day from school or childcare.  
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Box 2.
 
 
Description of the Imaginary Disease 
• The disease lasts for 15 years 
• During this time, your child: 
1. Is covered (face, body and arms) with up to 500 red spots that 
itch intensely, which is highly frustrating 
2. Has mild fever with cold-like symptoms  
3. Has problems sleeping 
4. Has no problems walking about 
5. Cannot go to school or day care  
6. Has problems with performing his/her usual activities (e.g. 
hobbies, sport, playing) 
 
 
